Corcept Wins FDA Approval for Lifyorli Ovarian Cancer Therapy

The latest update is out from Corcept Therapeutics ( (CORT) ).

On March 25, 2026, Corcept Therapeutics announced U.S. FDA approval of Lifyorli (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer previously treated with one to three regimens including bevacizumab. Lifyorli, the first FDA-approved selective glucocorticoid receptor antagonist, is an oral therapy that enhances chemotherapy sensitivity by counteracting cortisol’s suppression of apoptosis.

The approval rests on the pivotal Phase 3 ROSELLA trial, which enrolled 381 patients and showed a 35 percent reduction in risk of death and a 30 percent reduction in disease progression versus nab-paclitaxel alone, delivering a 4.1-month improvement in median overall survival. Investigators reported the combination was generally well tolerated with manageable safety risks such as neutropenia, infections and adrenal insufficiency, and leading oncologists and patient advocates indicated the regimen could become a new standard of care for this hard-to-treat population.

ROSELLA’s global enrollment across North America, Europe, Asia-Pacific and Latin America, along with prior data presentations at ASCO 2025 and publication in The Lancet, underscores the therapy’s clinical significance and international relevance. Corcept is also pursuing European commercialization, leveraging relacorilant’s orphan drug designation and a submitted marketing application to the EMA, positioning the company to expand its oncology footprint in a large, underserved market of women with platinum-resistant ovarian cancer.

The most recent analyst rating on (CORT) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.

Spark’s Take on CORT Stock

According to Spark, TipRanks’ AI Analyst, CORT is a Neutral.

The score is supported by strong financial quality (rapid revenue growth, very high gross margins, and a low-debt balance sheet) and a generally constructive earnings outlook with meaningful pipeline catalysts. It is constrained by clearly bearish technicals (price far below key moving averages with negative MACD), premium valuation (P/E ~41.7), and elevated regulatory/legal risks highlighted on the earnings call (CRL and patent ruling) alongside 2025 margin and cash-flow softening.

To see Spark’s full report on CORT stock, click here.

More about Corcept Therapeutics

Corcept Therapeutics, based in Redwood City, Calif., is a commercial-stage biopharmaceutical company focused on discovering and developing medications that treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of cortisol. The company is advancing its proprietary selective glucocorticoid receptor antagonist relacorilant across multiple cancers, including ovarian, endometrial, cervical, pancreatic and prostate tumors.

Average Trading Volume: 2,292,519

Technical Sentiment Signal: Sell

Current Market Cap: $3.58B

For a thorough assessment of CORT stock, go to TipRanks’ Stock Analysis page.